ReviewTransfusion2026
Estrogen as a therapeutic agent: Targeting endotheliopathy and coagulopathy in trauma.
Review in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTraumatic injury remains a leading cause of death, often due to uncontrolled hemorrhage and trauma-induced coagulopathy (TIC). TIC is critically triggered by the endotheliopathy of trauma, involving endothelial cell injury and glycocalyx degradation. Despite conventional advances, the stable casualty rate underscores the urgent need for new precision resuscitation strategies that acknowledge factors like biological sex.
designThe central hypothesis is that estrogen confers a survival advantage in hormonally active females through a dual action: endothelial cell stabilization (halting glycocalyx shedding) and its inherent procoagulant effect. The analysis assesses the therapeutic potential of both exogenous estrogen and female-derived blood products to mitigate endotheliopathy and coagulopathy.
resultsLiterature suggests that the female sex, particularly the pre-menopausal age group, possesses an intrinsic advantage linked to circulating estradiol. Estrogen supplementation is noted to mitigate bleeding risks, as clinical reviews in surgical and critical care settings consistently demonstrated a reduction in transfusion requirements and improved hemostasis after administering conjugated estrogen. Current literature findings underscore the therapeutic utility of estrogen in targeting endotheliopathy and coagulopathy.
conclusionThe evidence suggests that estrogen plays a critical, context-dependent role. One of the most compelling benefits is estrogen's capacity to maintain endothelial integrity, thereby correcting trauma-induced endotheliopathy. This mechanism, coupled with its inherent procoagulant effect, underlies the observed female survival advantage. Targeting this sex-based mechanism is a promising avenue to enhance trauma management. Future large-scale, randomized controlled trials are needed to validate the efficacy of direct estrogen supplementation and the strategic utilization of female-donated blood products in trauma resuscitation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.